Xeris Biopharma Holdings, Inc.

Listed Company

XERSCIK 0001867096NasdaqLarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$291.85M

Net Income

$554.0K

Total Assets

$383.53M

Equity

$13.69M

Shares Out

172.64M

Op. Cash Flow

$28.63M

XERS$8.81+68.36% · past yearDBEQ Basic

Daily closing prices

Business

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company developing and commercializing therapies for chronic endocrine and neurological diseases in the United States. The company markets three approved products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis, while advancing the Phase 3-ready candidate XP-8121, a once-weekly subcutaneous levothyroxine. Xeris leverages proprietary non-aqueous formulation technologies (XeriSol and XeriJect) to enable ready-to-use, room-temperature stable injectable formulations and pursues partnerships to license these technologies to other pharmaceutical companies.

Summary from 10-K filed 2026-03-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product revenue, net	292	203	164	110	50
Cost of goods sold	43	37	29	23	13
Research and development	31	26	22	21	25
Selling, general and administrative	182	163	146	138	126
Amortization of intangible assets	11	11	11	11	550,000
Total costs and expenses	267	237	208	192	165
Income (loss) from operations	25	−34	−44	−82	−115
Interest and other income	5	5	5	3	313,000
Loss on debt extinguishment, net	0	0	−3	−1	0
Debt refinancing costs	0	−3	0	0	—
Interest expense	−29	−31	−27	−14	—
Change in fair value of warrants	0	8,000	1,000	2	−702,000
Change in fair value of contingent value rights	0	4	5	−3	0
Total other expense	−24	−23	−19	−14	−8
Net income (loss) before income taxes	554,000	−57	−64	−96	−123
Income tax benefit	0	2	1	1	0
Net income (loss)	554,000	−55	−62	−95	−123
Unrealized gains (losses) on investments	0	0	−2,000	7,000	−38,000
Comprehensive income (loss)	554,000	−55	−62	−95	−123
Net loss per common share - basic (in dollars per share)	0	−0.37	−0.45	−0.7	−1.55
Net loss per common share - Diluted (in dollars per share)	0	−0.37	−0.45	−0.7	−1.55
Weighted average common shares outstanding - basic (in shares)	160	147	138	136	79
Weighted average common shares outstanding - Diluted (in shares)	173	147	138	136	79

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Trade accounts receivable, net	51	40	39	31	17
Inventory, net	69	48	39	25	18
Prepaid expenses and other current assets	10	7	6	9	5
Total current assets	240	168	156	187	143
Property and equipment, net	5	6	6	6	7
Operating lease right-of-use assets	22	23	23	4	0
Goodwill	23	23	23	23	23
Other assets	88	99	110	121	131
Other assets	5	5	5	5	829,000
Total assets	384	323	323	345	304
Accounts payable	3	2	12	5	9
Current portion of long-term debt	0	15	0	—	—
Current operating lease liabilities	6	6	3	2	0
Other accrued liabilities	33	28	24	37	49
Accrued trade discounts and rebates	43	29	22	17	15
Accrued returns reserve	19	19	14	11	4
Other current liabilities	5	1	1	3	2
Total current liabilities	110	100	95	74	79
Debt, net of unamortized debt issuance costs, non-current portion	220	217	191	—	—
Non-current operating lease liabilities	32	33	35	9	0
Other liabilities	8	2	5	31,000	2
Total liabilities	370	353	329	299	209
Commitments and contingencies (Note 14)	—	—	—	—	—
Preferred stockpar value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	0	0	0	0	0
Common stockpar value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 166,215,410 and 149,429,410 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	17,000	15,000	14,000	14,000	13,000
Additional paid in capital	685	642	610	600	555
Accumulated deficit	−671	−672	−617	−555	−460
Accumulated other comprehensive loss	−25,000	−25,000	−25,000	−23,000	−31,000
Total stockholders' equity (deficit)	14	−30	−7	45	95
Total liabilities and stockholders' equity (deficit)	384	323	323	345	304
Cash and cash equivalents	111	72	67	122	67

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1	1	1	1	1
Amortization of premium/discount on investments	0	−747,000	−1	184,000	413,000
Amortization of debt discount and debt issuance costs	3	3	2	2	1
Amortization of operating right-of-use assets	537,000	555,000	830,000	426,000	0
Deferred income tax expense (benefit)	0	−2	−1	−1	0
Stock-based compensation	22	18	11	12	11
Change in fair value of contingent value rights	0	−4	−5	3	0
Other	0	83,000	320,000	—	—
Trade accounts receivable	−11	−1	−8	−13	−6
Prepaid expenses and other current assets	−2	−2	3	−4	3
Inventory	−19	−9	−15	−7	−7
Accounts payable	−69,000	−10	7	−4	6
Other accrued liabilities	3	4	−6	−11	13
Accrued trade discounts and rebates	16	4	5	2	4
Accrued returns reserve	−113,000	5	3	—	—
Increase (Decrease) In Supply Agreement Liabilities	0	0	−7	−5	0
Operating lease liabilities	−2	1	8	−899,000	0
Other	4	−1	3	3	−1
Net cash provided by (used in) operating activities	29	−37	−47	−103	−96
Capital expenditures	−696,000	−868,000	−2	−524,000	−1
Purchases of investments	0	−34	−44	0	−43
Sales and maturities of investments	0	40	40	35	104
Net cash provided by (used in) investing activities	−696,000	5	−6	34	98
Proceeds from debt refinancing	0	50	0	0	—
Payment of debt discount	0	−12	0	0	—
Payments of debt issuance costs	0	0	−1	5	0
Proceeds from issuance of employee stock purchase plan shares	2	1	549,000	828,000	642,000
Proceeds from exercise of stock options	12	489,000	32,000	8,000	193,000
Proceeds from Issuance of Warrants	9	0	0	—	—
Repurchase of common stock withheld for taxes	−11	−4	−1	−468,000	−534,000
Net cash provided by (used in) financing activities	11	36	−2	127	27
Net cash provided by (used in) in cash, cash equivalents and restricted cash	39	4	−55	59	30
Cash paid for interest	27	27	28	11	7
Issuance of common shares in settlement of CVR liability	0	16	0	0	—
Issuance of convertible note	0	0	34	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Xeris Biopharma Holdings, Inc.'s CIK number?

Xeris Biopharma Holdings, Inc.'s SEC CIK number is 0001867096 (1867096). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Xeris Biopharma Holdings, Inc.'s SEC filings?

All of Xeris Biopharma Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Xeris Biopharma Holdings, Inc. last report earnings?

Xeris Biopharma Holdings, Inc. (XERS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001867096-26-000027). This is Xeris Biopharma Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Xeris Biopharma Holdings, Inc.'s most recent earnings 8-K?

Xeris Biopharma Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001867096-26-000027. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Xeris Biopharma Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →